Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III melanoma

Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III melanoma

Visit http://ecancer.org/ for more. At a press conference at ASCO 2014, Prof Eggermont (Erasmus University, Rotterdam, The Netherlands) talks about the initial efficacy and safety results from the EORTC 18071 phase III trial which looked at the use of ipilimumab versus placebo after complete resection of stage III melanoma.